Advertisement

Topics

Study: Dupixent Sales Contact Rates Lag at Sanofi/Regeneron

06:00 EDT 22 Aug 2017 | PharmPro

Uptake of Sanofi/Regeneron's Dupixent for atopic dermatitis strong, but sales representative contact rates leave something to be desired. Patient base grows, but nearly one-third of U.S. dermatologists have yet to see a sales representative.
Contributed Author: 
Spherix Global Insights
Topics: 

Original Article: Study: Dupixent Sales Contact Rates Lag at Sanofi/Regeneron

NEXT ARTICLE

More From BioPortfolio on "Study: Dupixent Sales Contact Rates Lag at Sanofi/Regeneron"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Dermatitis
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...